Skip to main content

Table 1 Patient characteristics, IFN-γ enzyme-linked immunosorbent spot, and serum HBV DNA levels of children with successful prophylactic treatment and their mothers.

From: Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus

Patient ID* Age
(years)
Gender Levels of serum hepatitis B surface antibodies
(mIU/mL)
Hepatitis B e antigen status Hepatitis B core antibody status Levels of serum ALT (IU/L) † core 117-125
(spots/106 PBMCs)
† pol 756-764
(spots/106 PBMCs)
Levels of serum hepatitis B virus DNA
(copies/mL)
M1 22    Pos Pos 18 14.1 17.6 > 108.8
C1 2 Female 84.7   Neg 16 0 5.0 100
M2 28    Neg Pos 13 0 0 104.0
C2 2 Male 40.6   Neg 17 0 8.9 80
M3 43    Neg Pos 10 4.5 0.9 103.2
C3a 11 Female 16.2   Neg 8 0 6.5 Neg
C3b 6 Male 172.1   Pos 17 0 0 Neg
M4 32    Neg Pos 11 30.8 47.3 103.1
C4 6 Male 28.2   Neg 15 13.9 94.4 Neg
M5 34    Neg Pos 37 0 0 103.0
C5a 8 Female 118.9   Neg 20 12.5 0 Neg
C5b 6 Female 63.4   Neg 13 68.0 114.3 80
M6 32    Neg Pos 17 48.2 8.2 103.7
C6a 6 Female 6.3   Neg 11 0 0 Neg
C6b 4 Female <5   Neg 12 40.0 0 Neg
C6c 2 Male <5   Neg 11 2.9 29.4 Neg
M7 40    Pos Pos 14 9.8 18.5 108.1
C7a 13 Male <5   Neg 18 0 0 Neg
C7b 4 Female 34.2   Neg 11 0 0 Neg
M8 22    Neg Pos 15 0 0 104.3
C8 0 Male 252.9   Pos 17 29.1 0 80
  1. * M and C indicate mother and child, respectively. Number indicates family ID. † More than 50 spots/106 PBMCs were defined as a significant HBV-specific T-cell response. PBMCs, peripheral blood mononuclear cells. Pos, positive Neg, negative